Pancreatic Cancer Research

ResearcherUniversity of LiverpoolNo recent work listed

Niall Christopher Tebbutt

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2613-5168; OpenAlex author ID A5080423970. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
72
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 3 papers

Papers 13

  1. ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenoc… Co-author DOI 10.1016/j.esmogo.2023.07.001↗
  2. Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population. Co-author DOI 10.1111/ajco.13807↗
  3. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  4. Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited int… Co-author DOI 10.1080/14737140.2022.2002689↗
  5. Stereotactic radiotherapy and the potential role of magnetic resonance-guided adaptive techniques for pancreatic cancer. Co-author DOI 10.3748/wjg.v28.i7.745↗
  6. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Co-author DOI 10.3390/cancers13225758↗
  7. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Co-author DOI 10.1093/annonc/mdz200↗
  8. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002557↗
  9. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0004-2↗
  10. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pa… Co-author DOI 10.1038/s41416-018-0005-1↗
  11. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  12. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. Co-author DOI 10.1093/jnci/djt347↗
  13. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced o… Last author DOI 10.1007/s10637-011-9687-4↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David Goldstein · 6 shared papers, 2018–2022 · strength 0.46
  2. Adnan M. Nagrial · 3 shared papers, 2019–2023 · strength 0.33
  3. Matthew Burge · 3 shared papers, 2019–2023 · strength 0.33
  4. Marion Harris · 3 shared papers, 2019–2023 · strength 0.33
  5. Belinda Lee · 3 shared papers, 2019–2023 · strength 0.33
  6. Alan Anthoney · 5 shared papers, 2014–2021 · strength 0.30
  7. Paula Ghaneh · 5 shared papers, 2014–2021 · strength 0.30
  8. Bengt L. G. Glimelius · 5 shared papers, 2014–2021 · strength 0.30
  9. Daniel H. Palmer · 5 shared papers, 2014–2021 · strength 0.30
  10. John P. Neoptolemos · 5 shared papers, 2014–2021 · strength 0.30
  11. Julia V. Mayerle · 5 shared papers, 2014–2021 · strength 0.30
  12. Juan W. Valle · 5 shared papers, 2014–2021 · strength 0.30
  13. Christopher Michael Halloran · 5 shared papers, 2014–2021 · strength 0.30
  14. Markus M. Lerch · 4 shared papers, 2018–2021 · strength 0.27
  15. Timothy Jay Price · 2 shared papers, 2022–2023 · strength 0.25
  16. Lorraine A. Chantrill · 2 shared papers, 2022–2023 · strength 0.25
  17. Christos Stelios Karapetis · 2 shared papers, 2022–2023 · strength 0.25
  18. Markus Wolfgang Büchler · 4 shared papers, 2014–2021 · strength 0.24
  19. William Greenhalf · 4 shared papers, 2014–2021 · strength 0.23
  20. Eithne Costello · 4 shared papers, 2014–2021 · strength 0.23
  21. Richard Charnley · 4 shared papers, 2014–2021 · strength 0.23
  22. Nils O. Elander · 3 shared papers, 2018–2021 · strength 0.21
  23. Karen Aughton · 3 shared papers, 2018–2021 · strength 0.21
  24. Christos Dervenis · 4 shared papers, 2014–2019 · strength 0.20
  25. Attila Oláh · 4 shared papers, 2014–2019 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.